Clarest Health

Clarest targets independent pharmacies, long-term care pharmacies, and medication therapy management providers that serve Medicare Advantage, Medicaid, and dual-eligible populations. The firm seeks businesses with established payer contracts and clinical workflows that can be integrated into its centralized platform. The services acquired typically generate revenue through both dispensing fees and clinical care management contracts with health plans.

Returns derive from two primary streams: operational improvements that increase dispensing margins and clinical contract revenue, and risk-based arrangements where health plans share savings generated by improved medication outcomes. Clarest's clinical model reduces adverse drug events and hospital readmissions, creating measurable savings that the firm partly captures through value-based contracts with payers.

No. The firm operates as a permanent capital holding company, not a traditional closed-end fund with fixed investment and exit periods. This structure supports indefinite hold periods for acquired pharmacy platforms, allowing clinical integration to mature over time without the pressure to sell assets according to a fund timeline.

Clarest pursues direct acquisitions of operating companies and does not allocate capital through third-party fund commitments. The firm deploys capital exclusively into wholly owned platforms where it can directly implement clinical protocols and control operational decisions.

The firm's acquisition activity is concentrated in the Eastern and Midwestern United States, where demographic profiles and payer market structures support scaled medication management platforms. There is no public evidence of expansion into Western or international markets at this time.